Key facts
- Biocompatibility Innovation’s last known valuation is $15.8M (Dec 2024).
- It has raised $3.3M; the latest was Seed Round ($1.2M) in Dec 2024.
- Notable investors include G-Factor.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Biocompatibility Innovation
- ·The full record, as it builds
Funding rounds
No funding rounds for Biocompatibility Innovation are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Biocompatibility Innovation
Developer of a biostealth technology platform designed to improve the biocompatibility and durability of medical devices and life-support equipment. The company offers pharmaceutical-grade, plant-based active molecules applied to prosthetic materials such as polymers, metals, alloys, and biological tissues, enabling manufacturers of medical devices to extend device lifespan, reduce patient care costs, and improve clinical outcomes.
- Sector
- Healthcare
- HQ
- Este, Italy
- Founded
- 2014
- Employees
- 8
- Website
- bci-biocompatibility.com/
- Ownership
- Privately Held (backing)
Biocompatibility Innovation doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Biocompatibility Innovation shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Biocompatibility Innovation in its N-PORT filings yet. We sweep new filings monthly.